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social life and expectations between women and men.
Deeper societal changes are needed to reduce the
inequities in pain experience between women and men.
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PHARMACOLOGICAL PAIN TREATMENT IN
AMBULATORY PRIMARY CARE PATIENTS
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OBJECTIVES: To develop a reliable, valid and sensitive
tool to assess satisfaction with pharmacological pain
treatment among primary care patients. METHODS:
Content sources for the initial version (IV) were biblio-
graphic review, focus groups with patients, and expert
opinion. IV was tested in a prospective study with ambu-
latory pain patients. Item-total statistics and exploratory
factor analysis (FA) were performed for item reduction.
The ﬁnal version (FV) was psychometrically assessed by:
internal consistency (Cronbach’s alpha—CA), test-retest
reliability in patients maintaining treatment (intraclass
correlation coefﬁcient ICC), convergent/discriminant
validity (SF-12 and pain intensity—VAS), construct valid-
ity (lineal multiple regression), extreme groups validity
for patients presenting pain relief (ROC curves) and
responsiveness in patients changing treatment (effect
size—ES). RESULTS: The IV was administered to 362
patients (58% women, age 51y, 48% suffering from
osteoarthritis). Four items were deleted from the IV
owing to a low item-scale homogeneity, leading-weight 
in FA and/or contribution to CA values. The ﬁnal FA
explained 70.2% of the variance. Four dimensions were
identiﬁed: adverse events (AE), speed-duration of effect,
functional beneﬁt and overall satisfaction. A total of
97.2% of patients full-completed the FV. CA for the
global score (GS) was 0.88 and over 0.80 for all dimen-
sions. ICC for GS was 0.73 and ranged from 0.59 (func-
tional beneﬁt) to 0.80 (AE). Correlations were low to
moderate with SF-12 (0.11–0.30) and moderate to good
with VAS (0.48 to 0.55, except AE, 0.20). Pain frequency,
intensity and relief were independently associated with
satisfaction GS, accounting for 43.5% of variance. Area
under the curve was 0.78 for GS and over 0.65 for all
dimensions (except AE, 0.57). ES were large for GS and
dimensions (0.8 to 2.5). CONCLUSIONS: This new 10-
item measure has proved to be reliable, valid and sensi-
tive to assess pharmacological pain treatment satisfaction
in primary care patients.
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Hanley KN, Peterman AH, Reynolds K, Caprini CA
Evanston Northwestern Health care, Evanston, IL, USA
OBJECTIVES: To compare patient reported outcomes of
pain and quality of life (QOL) between breast cancer
surgery patients. The analysis compared one patient
group that was on a critical pathway to a patient group
that was not on a critical pathway during their hospital
stay. METHODS: A quasi-experimental study of patients
discharged for breast cancer surgery at a community-
based teaching hospital. The analysis for this study
included 3 distinct patient-reported pain ratings 3–6 days
post-discharge: highest and lowest levels since discharge
and current level of pain at the time of assessment. Addi-
tionally, patients completed the Functional Assessment of
Cancer Therapy-Breast Subscale (FACT-B) six months
post-discharge. Data were collected via telephone inter-
view. RESULTS: Study groups were found to have similar
sociodemographic characteristics. There were no statisti-
cally signiﬁcant differences between the study groups for
the pain or QOL outcomes. Length of stay (LOS) was
found to be statistically signiﬁcant between the pathway
and non-pathway groups (p = 0.020). A total of 77.3%
of the pathway group and 76.7% of the non-pathway
reported pain ratings ≥3 when rating their highest level
of pain since discharge. CONCLUSIONS: Regardless of
pathway status, patients reported similar outcomes of
pain and QOL. The implementation of the pathway
helped formalize the care delivered at the institution.
While the ﬁndings illustrate consistent delivery of care
regardless of pathway status, they also indicate further
attention to pain management post-discharge is needed.
Over 75% of patients in both groups did not meet the
pathway standard when rating their highest level of pain.
The pathway can serve as an informative tool by identi-
fying areas for improvement. The data gathered can be
used as a baseline comparison measure once these areas
have been identiﬁed and changes implemented. Future
research should evaluate pathways and their impact on
patient care after a patient has been discharged from the
hospital.
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OBJECTIVES: To measure the willingness-to-pay of
patients who suffer from benign and intense chronic pain
and to investigate the relationship with the social and
demographic characteristics of the sample and the stated
and perceived quality of life. METHODS: Data from a
research on a sample of 205 and 158 patients suffering
from intense and chronic pain will be discussed, as in the
questionnaire it was asked how much every patient would
